V Square Quantitative Management LLC Purchases 1,778 Shares of Johnson & Johnson (NYSE:JNJ)

V Square Quantitative Management LLC boosted its position in Johnson & Johnson (NYSE:JNJ) by 3.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 47,319 shares of the company’s stock after purchasing an additional 1,778 shares during the quarter. Johnson & Johnson makes up 1.0% of V Square Quantitative Management LLC’s portfolio, making the stock its 12th biggest position. V Square Quantitative Management LLC’s holdings in Johnson & Johnson were worth $6,843,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. IFS Advisors LLC lifted its position in shares of Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after buying an additional 100 shares in the last quarter. Highline Wealth Partners LLC bought a new stake in Johnson & Johnson during the 3rd quarter valued at approximately $31,000. Bay Harbor Wealth Management LLC bought a new stake in Johnson & Johnson during the 4th quarter valued at approximately $32,000. RPg Family Wealth Advisory LLC bought a new stake in Johnson & Johnson during the 3rd quarter valued at approximately $35,000. Finally, Mowery & Schoenfeld Wealth Management LLC raised its stake in Johnson & Johnson by 58.7% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock valued at $40,000 after purchasing an additional 91 shares during the period. Institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the topic of a number of research reports. Barclays lifted their price objective on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Tuesday, January 28th. Raymond James dropped their target price on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a report on Thursday, January 23rd. Leerink Partners dropped their target price on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Finally, Bank of America dropped their target price on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a report on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $170.67.

Insider Transactions at Johnson & Johnson

In related news, Director Mark A. Weinberger acquired 1,000 shares of the stock in a transaction on Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Down 0.7 %

NYSE:JNJ opened at $156.20 on Tuesday. The company has a market cap of $376.08 billion, a P/E ratio of 23.49, a P/E/G ratio of 2.46 and a beta of 0.52. The stock’s fifty day moving average price is $147.87 and its two-hundred day moving average price is $155.95. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The company had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. During the same period in the prior year, the business posted $2.29 earnings per share. Johnson & Johnson’s revenue for the quarter was up 5.3% on a year-over-year basis. As a group, analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.18%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.